Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.
about
Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS)Screening of Drugs Inhibiting In vitro Oligomerization of Cu/Zn-Superoxide Dismutase with a Mutation Causing Amyotrophic Lateral SclerosisProteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosisDeuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic propertiesPyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosisExposure to an environmental neurotoxicant hastens the onset of amyotrophic lateral sclerosis-like phenotype in human Cu2+/Zn2+ superoxide dismutase 1 G93A mice: glutamate-mediated excitotoxicityCyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells.Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis.The preclinical discovery of amyotrophic lateral sclerosis drugs.Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS.Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis.Moving forward in clinical trials for ALS: motor neurons lead the way please.High content analysis in amyotrophic lateral sclerosis.A computational combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity.
P2860
Q24613709-BD79F28F-752A-4030-9273-E45C2231293CQ28831086-2E9D6835-9280-4F1E-A387-C91469754610Q34249469-D2B3A0C9-A7FA-40AE-91D8-7B582825B431Q34602618-F9B1F7C0-A146-4C4E-993F-6DDF67AA6DAEQ34779943-81D73BF4-CE7B-4CBA-83CA-C6609C813D4EQ35122901-04531ADA-5546-453B-A843-BCD4FB2519BFQ35675407-34F7E468-5793-4434-8A0F-F618AC0DCFBFQ35956262-24BCCF12-4B09-49ED-AAAD-A865253D8798Q36009915-ACCF239A-217A-4ABF-B1B2-98EB55EA37D7Q36108575-CB753E9B-C5FC-4399-B8F1-42D33B1FB71AQ36768705-8561E1C5-9B0D-4B54-B0FB-9C05867E5063Q38156505-0669A2BD-2FE8-497B-BBD0-F4D795E23513Q39037865-F5035E4F-936C-42FB-9BBB-22FC316EB6D3Q47741777-2ECAD89C-6BA7-4850-A9F3-5184AB8A2665
P2860
Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@ast
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@en
type
label
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@ast
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@en
prefLabel
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@ast
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@en
P2093
P2860
P1476
Identification of compounds pr ...... amyotrophic lateral sclerosis.
@en
P2093
Anthony C Arvanites
Donald R Kirsch
Radhia Benmohamed
Richard B Silverman
Richard I Morimoto
P2860
P356
10.3109/17482968.2010.522586
P577
2010-11-12T00:00:00Z